Boston Scientific (NYSE:BSX) Price Target Cut to $94.00 by Analysts at Wells Fargo & Company

Boston Scientific (NYSE:BSX) had its target price decreased by equities researchers at Wells Fargo & Company from $125.00 to $94.00 in a report issued on Thursday, Marketbeat reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target would suggest a potential upside of 20.14% from the company’s current price.

Several other equities research analysts have also commented on the stock. Evercore ISI set a $112.00 target price on shares of Boston Scientific in a research report on Monday, January 5th. Citigroup restated a “buy” rating on shares of Boston Scientific in a research report on Thursday. Morgan Stanley lowered their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday. National Bankshares set a $115.00 price objective on Boston Scientific in a research report on Monday. Finally, Canaccord Genuity Group set a $112.00 price objective on Boston Scientific in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $110.86.

Boston Scientific Stock Performance

Shares of BSX traded up $2.74 during midday trading on Thursday, reaching $78.24. 22,271,856 shares of the stock were exchanged, compared to its average volume of 15,930,081. The business’s 50-day moving average price is $94.37 and its 200 day moving average price is $99.13. The company has a market capitalization of $115.99 billion, a price-to-earnings ratio of 41.86, a PEG ratio of 1.63 and a beta of 0.67. Boston Scientific has a twelve month low of $74.86 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.51 and a quick ratio of 0.96.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.29 billion during the quarter, compared to analysts’ expectations of $5.29 billion. During the same period last year, the firm earned $0.70 EPS. The firm’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, sell-side analysts expect that Boston Scientific will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Boston Scientific

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Lockheed Martin Investment Management Co. grew its position in Boston Scientific by 12.0% in the 4th quarter. Lockheed Martin Investment Management Co. now owns 54,550 shares of the medical equipment provider’s stock worth $5,201,000 after purchasing an additional 5,840 shares during the last quarter. Commerzbank Aktiengesellschaft FI grew its stake in shares of Boston Scientific by 332.2% in the fourth quarter. Commerzbank Aktiengesellschaft FI now owns 64,500 shares of the medical equipment provider’s stock worth $6,150,000 after purchasing an additional 49,577 shares in the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of Boston Scientific by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after purchasing an additional 140 shares during the period. Bessemer Group Inc. raised its stake in shares of Boston Scientific by 34.2% during the fourth quarter. Bessemer Group Inc. now owns 3,896,966 shares of the medical equipment provider’s stock valued at $371,577,000 after purchasing an additional 993,753 shares in the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in Boston Scientific by 0.5% in the fourth quarter. Thrivent Financial for Lutherans now owns 639,120 shares of the medical equipment provider’s stock worth $60,978,000 after purchasing an additional 3,134 shares during the period. Institutional investors own 89.07% of the company’s stock.

Key Headlines Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 results beat expectations — EPS $0.80 vs. $0.78 consensus and revenue $5.29B (+15.9% year/year), with margin improvements and solid organic growth. This underpins the company’s longer-term growth story. Boston Scientific announces results for fourth quarter and full year 2025
• Positive Sentiment: Long-term research coverage highlights BSX as a growth stock based on Zacks style scores — a supportive narrative for buy-and-hold investors focused on medical-device secular trends. Why Boston Scientific (BSX) is a Top Growth Stock for the Long-Term
• Neutral Sentiment: Multiple analysts cut price targets after the print but largely kept buy/overweight ratings — signaling confidence in the franchise but tempered near-term estimates. The headline impact is mixed: sells on caution, but continued analyst support limits downside. Boston Scientific Analysts Cut Their Forecasts Following Q4 Results
• Negative Sentiment: Management’s modest FY2026 revenue and EPS guidance, plus softer-than-expected electrophysiology sales, sparked a large intra-day sell-off (stock plunged double-digits after the report) as investors reset growth expectations. That guidance concern remains the primary driver of recent weakness. Boston Scientific shares slide on cautious 2026 revenue forecast
• Negative Sentiment: Elevated bearish activity and insider selling add pressure — options flow showed a spike in put buying around the print, and CEO Michael Mahoney disclosed a large sale of ~160,901 shares, which can amplify short-term negative sentiment. Insider Selling: Boston Scientific (NYSE:BSX) CEO Sells 160,901 Shares of Stock

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.